Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02689284 · ClinicalTrials.gov registry record · Phase 1
Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
A Phase 1 study, sponsored by MacroGenics.
- Completed
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
NCT02689284 is a Phase 1 study that has completed, run by MacroGenics. The registered enrollment target is 95 participants.
The verdict
NCT02689284, a Phase 1 study, has completed, sponsored by MacroGenics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
Study Summary
This main purpose of this clinical study is to learn about the safety and activity of margetuximab and pembrolizumab combination treatment in patients with HER2+ gastric and gastroesophageal junction cancer.
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Margetuximab 10 mg/kg
- BIOLOGICAL Margetuximab 15 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2016-01 |
| Est. Completion | 2021-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02689284
The ClinicalTrials.gov registry entry for NCT02689284 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MacroGenics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT02689284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02689284 about?
NCT02689284 is a clinical study titled "Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer". This main purpose of this clinical study is to learn about the safety and activity of margetuximab and pembrolizumab combination treatment in patients with HER2+ gastric and gastroesophageal junction cancer.
What is the current status of trial NCT02689284?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2016-01. Estimated completion is 2021-01.
What interventions are being tested in trial NCT02689284?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Margetuximab 10 mg/kg (BIOLOGICAL), Margetuximab 15 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT02689284?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.